LAB vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Standard BioTools (LAB) exhibits severe operational distress, highlighted by a Piotroski F-Score of 0/9, indicating a total failure across all fundamental health benchmarks. While the company maintains a strong liquidity position with a Current Ratio of 4.19 and very low debt (D/E 0.07), these are offset by catastrophic profitability metrics and a sharp Q/Q revenue decline of 49.07%. The stock is currently trading near its 52-week low, reflecting a persistent bearish technical trend and a 5-year value erosion of over 80%. Despite a low Price-to-Book ratio of 0.72, the lack of revenue growth and deep operating losses suggest a value trap rather than a bargain.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
LAB vs LLY: Head-to-Head Comparison
This page compares Standard BioTools Inc. (LAB) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.